5'-adenosine monophosphate-activated protein kinase and the metabolic syndrome

Endocrine, Metabolic and Immune Disorders - Drug Targets

Volumn 11, Issue 3, 2011, Pages 206-216

  Mor, Vijay ^a   Unnikrishnan, M K ^a  

^a MANIPAL COLLEGE OF PHARMACEUTICAL SCIENCES   (India)

Author keywords

Adenosine monophosphate dependent kinase; Diabetes; Insulin resistance; Metabolic syndrome; Obesity

Indexed keywords

5' ADENOSINE MONOPHOSPHATE ACTIVATED PROTEIN KINASE; ADENOSINE PHOSPHATE; METFORMIN; PROTEIN KINASE; UNCLASSIFIED DRUG;

CARDIOVASCULAR SYSTEM; CELL GROWTH; CELL MATURATION; DRUG TARGETING; ENDOTHELIUM; ENZYME ACTIVATION; HEART HYPERTROPHY; HOMEOSTASIS; HUMAN; INFLAMMATION; INSULIN RESISTANCE; INTESTINE FLORA; KIDNEY FUNCTION; LIFESPAN; METABOLIC SYNDROME X; NEOPLASM; OBESITY; PATHOPHYSIOLOGY; REVIEW; THROMBOSIS;

EID: 79961064109     PISSN: 18715303     EISSN: 18715303     Source Type: Journal    
DOI: 10.2174/187153011796429844     Document Type: Review

References (163)

1. Iyer, A.; Fairlie, D.P.; Prins, J.B.; Hammock, B.D. and Brown, L. (2010) Inflammatory lipid mediators in adipocyte function and obesity. Nat. Rev. Endocrinol., 6, 71-82.
2. Cornier, M.A.; Dabelea, D.; Hernandez, T.L.; Lindstrom, R.C.; Steig, A.J.; Stob, N.R.; Van Pelt, R.E.; Wang, H. and Eckel, R.H. (2008) The metabolic syndrome. Endocr. Rev., 29, 777-822.
3. Hu, G.X.; Chen, G.R.; Xu, H.; Ge, R.S. and Lin, J. (2010) Activation of the AMP activated protein kinase by short-chain fatty acids is the main mechanism underlying the beneficial effect of a high fiber diet on the metabolic syndrome. Med. Hypotheses., 74, 123-126.
4. Jervell, J. (2000) Diabetes in international perspective. Tidsskr Nor Laegeforen, 120, 2686-2689.
5. The IDF consensus worldwide definition of the metabolic syndrome 2006. http://www.idf.org (Accessed January 26, 2011).
6. Simmons, R.K.; Alberti, K.G.; Gale, E.A.; Colagiuri, S.; Tuomilehto, J.; Qiao, Q.; Ramachandran, A.; Tajima, N.; Brajkovich Mirchov, I.; Ben-Nakhi, A.; Reaven, G.; Hama Sambo, B.; Mendis, S. and Roglic, G. (2010) The metabolic syndrome: useful concept or clinical tool? Report of a WHO Expert Consultation. Diabetologia, 53, 600-605.
7. Sadikot, S. and Hermans, M. (2010) Here we go again. . . The metabolic syndrome revisited! Diabetes and Metabolic Syndrome. Clinical Res. Rev., 4, 111-120.
8. Zimmet, P.A.G. The metabolic syndrome: perhaps an etiologic mystery but far from a myth-where does the International Diabetes Federation stand? Medscape Diabetes & Endocrinology. [Online], 2005. http://www.medscape.com/viewarticle/514211 (Accessed January 26, 2011).
9. Beg, Z.H.; Allmann, D.W. and Gibson, D.M. (1973) Modulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity with cAMP and wth protein fractions of rat liver cytosol. Biochem. Biophys. Res. Commun., 54, 1362-1369.
10. Carlson, C.A. and Kim, K.H. (1973) Regulation of hepatic acetyl coenzyme A carboxylase by phosphorylation and dephosphorylation. J. Biol. Chem., 248, 378-380.
11. Hardie, D.G. (2008) AMPK: a key regulator of energy balance in the single cell and the whole organism. Int. J. Obes. (Lond), 32 Suppl 4, S7-12.
12. Sanders, M.J.; Grondin, P.O.; Hegarty, B.D.; Snowden, M.A. and Carling, D. (2007) Investigating the mechanism for AMP activation of the AMP-activated protein kinase cascade. Biochem. J., 403, 139-148.
13. Oakhill, J.S.; Scott, J.W. and Kemp, B.E. (2009) Structure and function of AMP-activated protein kinase. Acta Physiol. (Oxf), 196, 3-14.
14. Zhou, G.; Myers, R.; Li, Y.; Chen, Y.; Shen, X.; Fenyk-Melody, J.; Wu, M.; Ventre, J.; Doebber, T.; Fujii, N.; Musi, N.; Hirshman, M.F.; Goodyear, L.J. and Moller, D.E. (2001) Role of AMPactivated protein kinase in mechanism of metformin action. J. Clin. Invest., 108, 1167-1174.
15. Zhou, G.; Sebhat, I.K. and Zhang, B.B. (2009) AMPK activators-- potential therapeutics for metabolic and other diseases. Acta Physiol. (Oxf)., 196, 175-190.
16. Kandadi, M.R.; Rajanna, P.K.; Unnikrishnan, M.K.; Boddu, S.P.; Hua, Y.; Li, J.; Du, M.; Ren, J. and Sreejayan, N. (2010) 2-(3,4- Dihydro-2H-pyrrolium-1-yl)-3oxoindan-1-olate (DHPO), a novel, synthetic small molecule that alleviates insulin resistance and lipid abnormalities. Biochem. Pharmacol., 79, 623-631.
17. Tseng, Y.H.; Cypess, A.M. and Kahn, C.R. (2010) Cellular bioenergetics as a target for obesity therapy. Nat. Rev. Drug Discov., 9, 465-482.
18. Kola, B.; Grossman, A.B. and Korbonits, M. (2008) The role of AMP-activated protein kinase in obesity. Front. Horm. Res., 36, 198-211.
19. Winder, W.W. and Hardie, D.G. (1996) Inactivation of acetyl-CoA carboxylase and activation of AMP-activated protein kinase in muscle during exercise. Am. J. Physiol., 270, E299-E304.
20. Osler, M.E. and Zierath, J.R. (2008) Adenosine 5'-monophosphateactivated protein kinase regulation of fatty acid oxidation in skeletal muscle. Endocrinology, 149, 935-941.
21. Vavvas, D.; Apazidis, A.; Saha, A.K.; Gamble, J.; Patel, A.; Kemp, B.E.; Witters, L.A. and Ruderman, N.B. (1997) Contractioninduced changes in acetyl-CoA carboxylase and 5'-AMP-activated kinase in skeletal muscle. J. Biol. Chem., 272, 13255-13261.
22. Storlien, L.; Oakes, N.D. and Kelley, D.E. (2004) Metabolic flexibility. Proc. Nutr. Soc., 63, 363-368.
23. Kelley, D.E. and Mandarino, L.J. (2000) Fuel selection in human skeletal muscle in insulin resistance: a reexamination. Diabetes, 49, 677-683.
24. Perwitz, N.; Wenzel, J.; Wagner, I.; Buning, J.; Drenckhan, M.; Zarse, K.; Ristow, M.; Lilienthal, W.; Lehnert, H. and Klein, J. (2010) Cannabinoid type 1 receptor blockade induces transdifferentiation towards a brown fat phenotype in white adipocytes. Diabetes Obes. Metab., 12, 158-166.
25. Woods, A.; Azzout-Marniche, D.; Foretz, M.; Stein, S.C.; Lemarchand, P.; Ferre, P.; Foufelle, F. and Carling, D. (2000) Characterization of the role of AMP-activated protein kinase in the regulation of glucose-activated gene expression using constitutively active and dominant negative forms of the kinase. Mol. Cell Biol., 20, 6704-6711.
26. Kahn, B.B.; Alquier, T.; Carling, D. and Hardie, D.G. (2005) AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab., 1, 15-25.
27. Lopez, M.; Lelliott, C.J. and Vidal-Puig, A. (2007) Hypothalamic fatty acid metabolism: a housekeeping pathway that regulates food intake. Bioessays, 29, 248-261.
28. Merrill, G.F.; Kurth, E.J.; Hardie, D.G. and Winder, W.W. (1997) AICA riboside increases AMP-activated protein kinase, fatty acid oxidation, and glucose uptake in rat muscle. Am. J. Physiol., 273, E1107-1112.
29. Martinez-Agustin, O.; Hernandez-Morante, J.J.; Martinez-Plata, E.; Sanchez de Medina, F. and Garaulet, M. (2010) Differences in AMPK expression between subcutaneous and visceral adipose tissue in morbid obesity. Regul. Pept., 163, 31-36.
30. Corton, J.M.; Gillespie, J.G.; Hawley, S.A. and Hardie, D.G. (1995) 5-aminoimidazole-4-carboxamide ribonucleoside. A specific method for activating AMP-activated protein kinase in intact cells? Eur. J. Biochem., 229, 558-565.
31. Daval, M.; Diot-Dupuy, F.; Bazin, R.; Hainault, I.; Viollet, B.; Vaulont, S.; Hajduch, E.; Ferre, P. and Foufelle, F. (2005) Antilipolytic action of AMP-activated protein kinase in rodent adipocytes. J. Biol. Chem., 280, 25250-25257.
32. Terada, S.; Goto, M.; Kato, M.; Kawanaka, K.; Shimokawa, T. and Tabata, I. (2002) Effects of low-intensity prolonged exercise on PGC-1 mRNA expression in rat epitrochlearis muscle. Biochem. Biophys. Res. Commun., 296, 350-354.
33. Zong, H.; Ren, J.M.; Young, L.H.; Pypaert, M.; Mu, J.; Birnbaum, M.J. and Shulman, G.I. (2002) AMP kinase is required for mitochondrial biogenesis in skeletal muscle in response to chronic energy deprivation. Proc. Natl. Acad. Sci. USA, 99, 15983-15987.
34. Lim, C.T.; Kola, B. and Korbonits, M. (2010) AMPK as a mediator of hormonal signalling. J. Mol. Endocrinol., 44, 87-97.
35. Minokoshi, Y.; Alquier, T.; Furukawa, N.; Kim, Y.B.; Lee, A.; Xue, B.; Mu, J.; Foufelle, F.; Ferre, P.; Birnbaum, M.J.; Stuck, B.J. and Kahn, B.B. (2004) AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus. Nature, 428, 569-574.
36. Xue, B. and Kahn, B.B. (2006) AMPK integrates nutrient and hormonal signals to regulate food intake and energy balance through effects in the hypothalamus and peripheral tissues. J. Physiol., 574, 73-83.
37. Hayes, M.R.; Bradley, L. and Grill, H.J. (2009) Endogenous hindbrain glucagon-like peptide-1 receptor activation contributes to the control of food intake by mediating gastric satiation signaling. Endocrinology, 150, 2654-2659.
38. Ferré, P. and Foufelle, F. (2011) A New Role for a Metabolic Star: AMP-Activated Protein Kinase Stimulates Fat Absorption. Cell metabolism, 13, 1-2.
39. Dzamko, N.; van Denderen, B.J.; Hevener, A.L.; Jorgensen, S.B.; Honeyman, J.; Galic, S.; Chen, Z.P.; Watt, M.J.; Campbell, D.J.; Steinberg, G.R. and Kemp, B.E. (2010) AMPK beta1 deletion reduces appetite, preventing obesity and hepatic insulin resistance. J. Biol. Chem., 285, 115-122.
40. John, U.; Hanke, M.; Rumpf, H.J. and Thyrian, J.R. (2005) Smoking status, cigarettes per day, and their relationship to overweight and obesity among former and current smokers in a national adult general population sample. Int. J. Obes. (Lond), 29, 1289-1294.
41. An, Z.; Wang, H.; Song, P.; Zhang, M.; Geng, X. and Zou, M.H. (2007) Nicotine-induced activation of AMP-activated protein kinase inhibits fatty acid synthase in 3T3L1 adipocytes: a role for oxidant stress. J. Biol. Chem., 282, 26793-26801.
42. Miller, R.G.; Petajan, J.H.; Bryan, W.W.; Armon, C.; Barohn, R.J.; Goodpasture, J.C.; Hoagland, R.J.; Parry, G.J.; Ross, M.A. and Stromatt, S.C. (1996) A placebo-controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis. rhCNTF ALS Study Group. Ann. Neurol., 39, 256-260.
43. Steinberg, G.R.; Watt, M.J.; Fam, B.C.; Proietto, J.; Andrikopoulos, S.; Allen, A.M.; Febbraio, M.A. and Kemp, B.E. (2006) Ciliary neurotrophic factor suppresses hypothalamic AMP-kinase signaling in leptin-resistant obese mice. Endocrinology, 147, 3906-3914.
44. Backhed, F.; Manchester, J.K.; Semenkovich, C.F. and Gordon, J.I. (2007) Mechanisms underlying the resistance to dietinduced obesity in germ-free mice. Proc. Natl. Acad. Sci. USA, 104, 979-984.
45. Kelley, D.E.; Goodpaster, B.; Wing, R.R. and Simoneau, J.A. (1999) Skeletal muscle fatty acid metabolism in association with insulin resistance, obesity, and weight loss. Am. J. Physiol., 277, E1130-E1141.
46. Petersen, K.F.; Dufour, S.; Befroy, D.; Garcia, R. and Shulman, G.I. (2004) Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N. Engl. J. Med., 350, 664-671.
47. Koves, T.R.; Ussher, J.R.; Noland, R.C.; Slentz, D.; Mosedale, M.; Ilkayeva, O.; Bain, J.; Stevens, R.; Dyck, J.R.; Newgard, C.B.; Lopaschuk, G.D. and Muoio, D.M. (2008) Mitochondrial overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin resistance. Cell Metab., 7, 45-56.
48. Lochhead, P.A.; Salt, I.P.; Walker, K.S.; Hardie, D.G. and Sutherland, C. (2000) 5-aminoimidazole-4-carboxamide riboside mimics the effects of insulin on the expression of the 2 key gluconeogenic genes PEPCK and glucose-6-phosphatase. Diabetes, 49, 896-903.
49. Horike, N.; Sakoda, H.; Kushiyama, A.; Ono, H.; Fujishiro, M.; Kamata, H.; Nishiyama, K.; Uchijima, Y.; Kurihara, Y.; Kurihara, H. and Asano, T. (2008) AMP-activated protein kinase activation increases phosphorylation of glycogen synthase kinase 3beta and thereby reduces cAMP-responsive element transcriptional activity and phosphoenolpyruvate carboxykinase C gene expression in the liver. J. Biol. Chem., 283, 33902-33910.
50. Yamauchi, T.; Kamon, J.; Minokoshi, Y.; Ito, Y.; Waki, H.; Uchida, S.; Yamashita, S.; Noda, M.; Kita, S.; Ueki, K.; Eto, K.; Akanuma, Y.; Froguel, P.; Foufelle, F.; Ferre, P.; Carling, D.; Kimura, S.; Nagai, R.; Kahn, B.B. and Kadowaki, T. (2002) Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat. Med., 8, 1288-1295.
51. Bergeron, R.; Previs, S.F.; Cline, G.W.; Perret, P.; Russell, R.R., 3rd; Young, L.H. and Shulman, G.I. (2001) Effect of 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside infusion on in vivo glucose and lipid metabolism in lean and obese Zucker rats. Diabetes, 50, 1076-1082.
52. Hundal, R.S.; Krssak, M.; Dufour, S.; Laurent, D.; Lebon, V.; Chandramouli, V.; Inzucchi, S.E.; Schumann, W.C.; Petersen, K.F.; Landau, B.R. and Shulman, G.I. (2000) Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes, 49, 2063-2069.
53. Shaw, R.J.; Lamia, K.A.; Vasquez, D.; Koo, S.H.; Bardeesy, N.; Depinho, R.A.; Montminy, M. and Cantley, L.C. (2005) The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science, 310, 1642-1646.
54. Muoio, D.M.; Seefeld, K.; Witters, L.A. and Coleman, R.A. (1999) AMP-activated kinase reciprocally regulates triacylglycerol synthesis and fatty acid oxidation in liver and muscle: evidence that sn-glycerol-3-phosphate acyltransferase is a novel target. Biochem. J., 338, 783-791.
55. Narkar, V.A.; Downes, M.; Yu, R.T.; Embler, E.; Wang, Y.X.; Banayo, E.; Mihaylova, M.M.; Nelson, M.C.; Zou, Y.; Juguilon, H.; Kang, H.; Shaw, R.J. and Evans, R.M. (2008) AMPK and PPARdelta agonists are exercise mimetics. Cell, 134, 405-415.
56. Sriwijitkamol, A.; Coletta, D.K.; Wajcberg, E.; Balbontin, G.B.; Reyna, S.M.; Barrientes, J.; Eagan, P.A.; Jenkinson, C.P.; Cersosimo, E.; DeFronzo, R.A.; Sakamoto, K. and Musi, N. (2007) Effect of acute exercise on AMPK signaling in skeletal muscle of subjects with type 2 diabetes: a time-course and dose-response study. Diabetes, 56, 836-848.
57. De Filippis, E.; Alvarez, G.; Berria, R.; Cusi, K.; Everman, S.; Meyer, C. and Mandarino, L.J. (2008) Insulin-resistant muscle is exercise resistant: evidence for reduced response of nuclearencoded mitochondrial genes to exercise. Am. J. Physiol. Endocrinol. Metab., 294, E607-E614.
58. Koistinen, H.A.; Galuska, D.; Chibalin, A.V.; Yang, J.; Zierath, J.R.; Holman, G.D. and Wallberg-Henriksson, H. (2003) 5-aminoimidazole carboxamide riboside increases glucose transport and cell-surface GLUT4 content in skeletal muscle from subjects with type 2 diabetes. Diabetes, 52, 1066-1072.
59. Ruderman, N.B.; Saha, A.K. and Kraegen, E.W. (2003) Minireview: malonyl CoA, AMP-activated protein kinase, and adiposity. Endocrinology, 144, 5166-5171.
60. Suwa, M.; Nakano, H. and Kumagai, S. (2003) Effects of chronic AICAR treatment on fiber composition, enzyme activity, UCP3, and PGC-1 in rat muscles. J. Appl. Physiol., 95, 960-968.
61. Jager, S.; Handschin, C.; St-Pierre, J. and Spiegelman, B.M. (2007) AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1alpha. Proc. Natl. Acad. Sci. USA, 104, 12017-12022.
62. Holmes, B.F.; Kurth-Kraczek, E.J. and Winder, W.W. (1999) Chronic activation of 5'-AMP-activated protein kinase increases GLUT-4, hexokinase, and glycogen in muscle. J. Appl. Physiol., 87, 1990-1995.
63. Kelley, D.E.; He, J.; Menshikova, E.V. and Ritov, V.B. (2002) Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes. Diabetes, 51, 2944-2950.
64. Canto, C.; Gerhart-Hines, Z.; Feige, J.N.; Lagouge, M.; Noriega, L.; Milne, J.C.; Elliott, P.J.; Puigserver, P. and Auwerx, J. (2009) AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity. Nature, 458, 1056-1060.
65. Ha, S.K.; Kim, J. and Chae, C. (2011) Role of AMP-activated Protein Kinase and Adiponectin during Development of Hepatic Steatosis in High-fat Diet-induced Obesity in Rats. J. Comp. Pathol., 145, 88-94.
66. Gami, A.S.; Witt, B.J.; Howard, D.E.; Erwin, P.J.; Gami, L.A.; Somers, V.K. and Montori, V.M. (2007) Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J. Am. Coll. Cardiol., 49, 403-414.
67. Kudo, N.; Barr, A.J.; Barr, R.L.; Desai, S. and Lopaschuk, G.D. (1995) High rates of fatty acid oxidation during reperfusion of ischemic hearts are associated with a decrease in malonyl- CoA levels due to an increase in 5'-AMP-activated protein kinase inhibition of acetyl-CoA carboxylase. J. Biol. Chem., 270, 17513-17520.
68. Russell, R.R., 3rd; Li, J.; Coven, D.L.; Pypaert, M.; Zechner, C.; Palmeri, M.; Giordano, F.J.; Mu, J.; Birnbaum, M.J. and Young, L.H. (2004) AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury. J. Clin. Invest., 114, 495-503.
69. Marsin, A.S.; Bertrand, L.; Rider, M.H.; Deprez, J.; Beauloye, C.; Vincent, M.F.; Van den Berghe, G.; Carling, D. and Hue, L. (2000) Phosphorylation and activation of heart PFK-2 by AMPK has a role in the stimulation of glycolysis during ischaemia. Curr. Biol., 10, 1247-1255.
70. Russell, R.R., 3rd; Bergeron, R.; Shulman, G.I. and Young, L.H. (1999) Translocation of myocardial GLUT-4 and increased glucose uptake through activation of AMPK by AICAR. Am. J. Physiol., 277, H643-649.
71. Yang, J. and Holman, G.D. (2006) Long-term metformin treatment stimulates cardiomyocyte glucose transport through an AMP-activated protein kinase-dependent reduction in GLUT4 endocytosis. Endocrinology, 147, 2728-2736.
72. Kristiansen, S.B.; Solskov, L.; Jessen, N.; Lofgren, B.; Schmitz, O.; Nielsen-Kudsk, J.E.; Nielsen, T.T.; Botker, H.E. and Lund, S. (2009) 5-Aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside increases myocardial glucose uptake during reperfusion and induces late pre-conditioning: potential role of AMP-activated protein kinase. Basic Clin. Pharmacol. Toxicol., 105, 10-16.
73. Calvert, J.W.; Gundewar, S.; Jha, S.; Greer, J.J.; Bestermann, W.H.; Tian, R. and Lefer, D.J. (2008) Acute metformin therapy confers cardioprotection against myocardial infarction via AMPKeNOS- mediated signaling. Diabetes, 57, 696-705.
74. An, D.; Pulinilkunnil, T.; Qi, D.; Ghosh, S.; Abrahani, A. and Rodrigues, B. (2005) The metabolic switch AMPK regulates cardiac heparin-releasable lipoprotein lipase. Am. J. Physiol. Endocrinol. Metab., 288, E246-E253.
75. Kim, J.E.; Kim, Y.W.; Lee, I.K.; Kim, J.Y.; Kang, Y.J. and Park, S.Y. (2008) AMP-activated protein kinase activation by 5- aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAR) inhibits palmitate-induced endothelial cell apoptosis through reactive oxygen species suppression. J. Pharmacol. Sci., 106, 394-403.
76. Hauton, D. (2010) Does long-term metformin treatment increase cardiac lipoprotein lipase? Metabolism, 60, 32-42.
77. Miller, E.J.; Li, J.; Leng, L.; McDonald, C.; Atsumi, T.; Bucala, R. and Young, L.H. (2008) Macrophage migration inhibitory factor stimulates AMP-activated protein kinase in the ischaemic heart. Nature, 451, 578-582.
78. Ma, H.; Wang, J.; Thomas, D.P.; Tong, C.; Leng, L.; Wang, W.; Merk, M.; Zierow, S.; Bernhagen, J.; Ren, J.; Bucala, R. and Li, J. (2010) Impaired macrophage migration inhibitory factor-AMP activated protein kinase activation and ischemic recovery in the senescent heart. Circulation, 122, 282-292.
79. Gundewar, S.; Calvert, J.W.; Jha, S.; Toedt-Pingel, I.; Ji, S.Y.; Nunez, D.; Ramachandran, A.; Anaya-Cisneros, M.; Tian, R. and Lefer, D.J. (2009) Activation of AMP-activated protein kinase by metformin improves left ventricular function and survival in heart failure. Circ. Res., 104, 403-411.
80. Shibata, R.; Sato, K.; Pimentel, D.R.; Takemura, Y.; Kihara, S.; Ohashi, K.; Funahashi, T.; Ouchi, N. and Walsh, K. (2005) Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms. Nat. Med., 11, 1096-1103.
81. Dyck, J.R. and Lopaschuk, G.D. (2006) AMPK alterations in cardiac physiology and pathology: enemy or ally? J. Physiol., 574, 95-112.
82. Hendrickson, S.C.; St Louis, J.D.; Lowe, J.E. and Abdel-aleem, S. (1997) Free fatty acid metabolism during myocardial ischemia and reperfusion. Mol. Cell Biochem., 166, 85-94.
83. Lopaschuk, G.D. and Spafford, M.A. (1990) Energy substrate utilization by isolated working hearts from newborn rabbits. Am. J. Physiol., 258, H1274-1280.
84. Lopaschuk, G.D.; Wambolt, R.B. and Barr, R.L. (1993) An imbalance between glycolysis and glucose oxidation is a possible explanation for the detrimental effects of high levels of fatty acids during aerobic reperfusion of ischemic hearts. J. Pharmacol. Exp. Ther., 264, 135-144.
85. Lopaschuk, G.D. (1997) Alterations in fatty acid oxidation during reperfusion of the heart after myocardial ischemia. Am. J. Cardiol., 80, 11A-16A.
86. Dyck, J.R.; Cheng, J.F.; Stanley, W.C.; Barr, R.; Chandler, M.P.; Brown, S.; Wallace, D.; Arrhenius, T.; Harmon, C.; Yang, G.; Nadzan, A.M. and Lopaschuk, G.D. (2004) Malonyl coenzyme a decarboxylase inhibition protects the ischemic heart by inhibiting fatty acid oxidation and stimulating glucose oxidation. Circ. Res., 94, e78-84.
87. Kim, M. and Tian, R. (2011) Targeting AMPK for cardiac protection: Opportunities and challenges. J. Mol. Cell. Cardiol., In Press, Corrected Proof,
88. Allard, M.F.; Schonekess, B.O.; Henning, S.L.; English, D.R. and Lopaschuk, G.D. (1994) Contribution of oxidative metabolism and glycolysis to ATP production in hypertrophied hearts. Am. J. Physiol., 267, H742-750.
89. Xing, Y.; Musi, N.; Fujii, N.; Zou, L.; Luptak, I.; Hirshman, M.F.; Goodyear, L.J. and Tian, R. (2003) Glucose metabolism and energy homeostasis in mouse hearts overexpressing dominant negative alpha2 subunit of AMP-activated protein kinase. J. Biol. Chem., 278, 28372-28377.
90. Tian, R.; Musi, N.; D'Agostino, J.; Hirshman, M.F. and Goodyear, L.J. (2001) Increased adenosine monophosphate-activated protein kinase activity in rat hearts with pressure-overload hypertrophy. Circulation, 104, 1664-1669.
91. Krause, U.; Bertrand, L. and Hue, L. (2002) Control of p70 ribosomal protein S6 kinase and acetyl-CoA carboxylase by AMPactivated protein kinase and protein phosphatases in isolated hepatocytes. Eur. J. Biochem., 269, 3751-3759.
92. Horman, S.; Browne, G.; Krause, U.; Patel, J.; Vertommen, D.; Bertrand, L.; Lavoinne, A.; Hue, L.; Proud, C. and Rider, M. (2002) Activation of AMP-activated protein kinase leads to the phosphorylation of elongation factor 2 and an inhibition of protein synthesis. Curr. Biol., 12, 1419-1423.
93. Chan, A.Y.; Soltys, C.L.; Young, M.E.; Proud, C.G. and Dyck, J.R. (2004) Activation of AMP-activated protein kinase inhibits protein synthesis associated with hypertrophy in the cardiac myocyte. J. Biol. Chem., 279, 32771-32779.
94. Ikeda, Y.; Sato, K.; Pimentel, D.R.; Sam, F.; Shaw, R.J.; Dyck, J.R. and Walsh, K. (2009) Cardiac-specific deletion of LKB1 leads to hypertrophy and dysfunction. J. Biol. Chem., 284, 35839-35849.
95. Turdi, S.; Kandadi, M.R.; Zhao, J.; Huff, A.F.; Du, M. and Ren, J. (2011) Deficiency in AMP-activated protein kinase exaggerates high fat diet-induced cardiac hypertrophy and contractile dysfunction. J. Mol. Cell. Cardiol., 150, 712-722.
96. Gollob, M.H.; Green, M.S.; Tang, A.S.; Gollob, T.; Karibe, A.; Ali Hassan, A.S.; Ahmad, F.; Lozado, R.; Shah, G.; Fananapazir, L.; Bachinski, L.L. and Roberts, R. (2001) Identification of a gene responsible for familial Wolff-Parkinson-White syndrome. N. Engl. J. Med., 344, 1823-1831.
97. Davies, J.K.; Wells, D.J.; Liu, K.; Whitrow, H.R.; Daniel, T.D.; Grignani, R.; Lygate, C.A.; Schneider, J.E.; Noel, G.; Watkins, H. and Carling, D. (2006) Characterization of the role of gamma2 R531G mutation in AMP-activated protein kinase in cardiac hypertrophy and Wolff-Parkinson-White syndrome. Am. J. Physiol. Heart Circ. Physiol., 290, H1942-1951.
98. Murphy, R.T.; Mogensen, J.; McGarry, K.; Bahl, A.; Evans, A.; Osman, E.; Syrris, P.; Gorman, G.; Farrell, M.; Holton, J.L.; Hanna, M.G.; Hughes, S.; Elliott, P.M.; Macrae, C.A. and McKenna, W.J. (2005) Adenosine monophosphate-activated protein kinase disease mimicks hypertrophic cardiomyopathy and Wolff-Parkinson-White syndrome: natural history. J. Am. Coll. Cardiol., 45, 922-930.
99. Banerjee, S.K.; McGaffin, K.R.; Huang, X.N. and Ahmad, F. (2010) Activation of cardiac hypertrophic signaling pathways in a transgenic mouse with the human PRKAG2 Thr400Asn mutation. Biochim. Biophys. Acta., 1802, 284-291.
100. Chan, A.Y.; Dolinsky, V.W.; Soltys, C.L.; Viollet, B.; Baksh, S.; Light, P.E. and Dyck, J.R. (2008) Resveratrol inhibits cardiac hypertrophy via AMP-activated protein kinase and Akt. J. Biol. Chem., 283, 24194-24201.
101. Dolinsky, V.W.; Chan, A.Y.; Robillard Frayne, I.; Light, P.E.; Des Rosiers, C. and Dyck, J.R. (2009) Resveratrol prevents the prohypertrophic effects of oxidative stress on LKB1. Circulation, 119, 1643-1652.
102. Sasaki, H.; Asanuma, H.; Fujita, M.; Takahama, H.; Wakeno, M.; Ito, S.; Ogai, A.; Asakura, M.; Kim, J.; Minamino, T.; Takashima, S.; Sanada, S.; Sugimachi, M.; Komamura, K.; Mochizuki, N. and Kitakaze, M. (2009) Metformin prevents progression of heart failure in dogs: role of AMP-activated protein kinase. Circulation, 119, 2568-2577.
103. Wang, C.; Li, L.; Zhang, Z.G.; Fan, D.; Zhu, Y. and Wu, L.L. (2010) Globular adiponectin inhibits angiotensin II-induced nuclear factor kappaB activation through AMP-activated protein kinase in cardiac hypertrophy. J. Cell. Physiol., 222, 149-155.
104. Shimano, M.; Ouchi, N.; Shibata, R.; Ohashi, K.; Pimentel, D.R.; Murohara, T. and Walsh, K. (2010) Adiponectin deficiency exacerbates cardiac dysfunction following pressure overload through disruption of an AMPK-dependent angiogenic response. J. Mol. Cell Cardiol., 49, 210-220.
105. Shibata, R.; Ouchi, N.; Ito, M.; Kihara, S.; Shiojima, I.; Pimentel, D.R.; Kumada, M.; Sato, K.; Schiekofer, S.; Ohashi, K.; Funahashi, T.; Colucci, W.S. and Walsh, K. (2004) Adiponectin-mediated modulation of hypertrophic signals in the heart. Nat. Med., 10, 1384-1389.
106. Hattori, Y.; Suzuki, K.; Hattori, S. and Kasai, K. (2006) Metformin inhibits cytokine-induced nuclear factor kappaB activation via AMP-activated protein kinase activation in vascular endothelial cells. Hypertension, 47, 1183-1188.
107. Kobayashi, H.; Ouchi, N.; Kihara, S.; Walsh, K.; Kumada, M.; Abe, Y.; Funahashi, T. and Matsuzawa, Y. (2004) Selective suppression of endothelial cell apoptosis by the high molecular weight form of adiponectin. Circ. Res., 94, e27-31.
108. Morrow, V.A.; Foufelle, F.; Connell, J.M.; Petrie, J.R.; Gould, G.W. and Salt, I.P. (2003) Direct activation of AMP-activated protein kinase stimulates nitric-oxide synthesis in human aortic endothelial cells. J. Biol. Chem., 278, 31629-31639.
109. Xie, Z.; Dong, Y.; Scholz, R.; Neumann, D. and Zou, M.H. (2008) Phosphorylation of LKB1 at serine 428 by protein kinase C-zeta is required for metformin-enhanced activation of the AMP-activated protein kinase in endothelial cells. Circulation, 117, 952-962.
110. Boyle, J.G.; Logan, P.J.; Ewart, M.A.; Reihill, J.A.; Ritchie, S.A.; Connell, J.M.; Cleland, S.J. and Salt, I.P. (2008) Rosiglitazone stimulates nitric oxide synthesis in human aortic endothelial cells via AMP-activated protein kinase. J. Biol. Chem., 283, 11210-11217.
111. Bradley, E.A.; Eringa, E.C.; Stehouwer, C.D.; Korstjens, I.; van Nieuw Amerongen, G.P.; Musters, R.; Sipkema, P.; Clark, M.G. and Rattigan, S. (2010) Activation of AMP-activated protein kinase by 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside in the muscle microcirculation increases nitric oxide synthesis and microvascular perfusion. Arterioscler. Thromb. Vasc. Biol., 30, 1137-1142.
112. Lee, M.; Hwang, J.T.; Lee, H.J.; Jung, S.N.; Kang, I.; Chi, S.G.; Kim, S.S. and Ha, J. (2003) AMP-activated protein kinase activity is critical for hypoxia-inducible factor-1 transcriptional activity and its target gene expression under hypoxic conditions in DU145 cells. J. Biol. Chem., 278, 39653-39661.
113. Reihill, J.A.; Ewart, M.A.; Hardie, D.G. and Salt, I.P. (2007) AMPactivated protein kinase mediates VEGF-stimulated endothelial NO production. Biochem. Biophys. Res. Commun., 354, 1084-1088.
114. Nagata, D.; Takeda, R.; Sata, M.; Satonaka, H.; Suzuki, E.; Nagano, T. and Hirata, Y. (2004) AMP-activated protein kinase inhibits angiotensin II-stimulated vascular smooth muscle cell proliferation. Circulation, 110, 444-451.
115. Stahmann, N.; Woods, A.; Spengler, K.; Heslegrave, A.; Bauer, R.; Krause, S.; Viollet, B.; Carling, D. and Heller, R. (2010) Activation of AMP-activated protein kinase by vascular endothelial growth factor mediates endothelial angiogenesis independently of nitricoxide synthase. J. Biol. Chem., 285, 10638-10652.
116. Izumi, Y.; Shiota, M.; Kusakabe, H.; Hikita, Y.; Nakao, T.; Nakamura, Y.; Muro, T.; Miura, K.; Yoshiyama, M. and Iwao, H. (2009) Pravastatin accelerates ischemia-induced angiogenesis through AMP-activated protein kinase. Hypertens. Res., 32, 675-679.
117. Dong, Y.; Zhang, M.; Wang, S.; Liang, B.; Zhao, Z.; Liu, C.; Wu, M.; Choi, H.C.; Lyons, T.J. and Zou, M.H. (2010) Activation of AMP-activated protein kinase inhibits oxidized LDL-triggered endoplasmic reticulum stress in vivo. Diabetes, 59, 1386-1396.
118. Ishii, N.; Matsumura, T.; Kinoshita, H.; Motoshima, H.; Kojima, K.; Tsutsumi, A.; Kawasaki, S.; Yano, M.; Senokuchi, T.; Asano, T.; Nishikawa, T. and Araki, E. (2009) Activation of AMPactivated protein kinase suppresses oxidized low-density lipoprotein-induced macrophage proliferation. J. Biol. Chem., 284, 34561-34569.
119. Dong, Y.; Zhang, M.; Liang, B.; Xie, Z.; Zhao, Z.; Asfa, S.; Choi, H.C. and Zou, M.H. (2010) Reduction of AMP-activated protein kinase alpha2 increases endoplasmic reticulum stress and atherosclerosis in vivo. Circulation, 121, 792-803.
120. Kimura, T.; Tomura, H.; Sato, K.; Ito, M.; Matsuoka, I.; Im, D.S.; Kuwabara, A.; Mogi, C.; Itoh, H.; Kurose, H.; Murakami, M. and Okajima, F. (2010) Mechanism and role of high density lipoprotein-induced activation of AMP-activated protein kinase in endothelial cells. J. Biol. Chem., 285, 4387-4397.
121. Taub, M.; Springate, J.E. and Cutuli, F. (2010) Targeting of renal proximal tubule Na,K-ATPase by salt-inducible kinase. Biochem. Biophys. Res. Commun., 393, 339-344.
122. Fraser, S.; Mount, P.; Hill, R.; Levidiotis, V.; Katsis, F.; Stapleton, D.; Kemp, B.E. and Power, D.A. (2005) Regulation of the energy sensor AMP-activated protein kinase in the kidney by dietary salt intake and osmolality. Am. J. Physiol. Renal. Physiol., 288, F578-586.
123. Hallows, K.R.; Mount, P.F.; Pastor-Soler, N.M. and Power, D.A. (2010) Role of the energy sensor AMP-activated protein kinase in renal physiology and disease. Am. J. Physiol. Renal. Physiol.,[Epub ahead of print]
124. Iyer, A.; Panchal, S.; Poudyal, H. and Brown, L. (2009) Potential health benefits of Indian spices in the symptoms of the metabolic syndrome: a review. Indian J. Biochem. Biophys., 46, 467-481.
125. Ko, H.J.; Zhang, Z.; Jung, D.Y.; Jun, J.Y.; Ma, Z.; Jones, K.E.; Chan, S.Y. and Kim, J.K. (2009) Nutrient stress activates inflammation and reduces glucose metabolism by suppressing AMP-activated protein kinase in the heart. Diabetes, 58, 2536-2546.
126. Katerelos, M.; Mudge, S.J.; Stapleton, D.; Auwardt, R.B.; Fraser, S.A.; Chen, C.G.; Kemp, B.E. and Power, D.A. (2010) 5- aminoimidazole-4-carboxamide ribonucleoside and AMP-activated protein kinase inhibit signalling through NF-kappaB. Immunol. Cell Biol., 88, 754-760.
127. Li, X.N.; Song, J.; Zhang, L.; LeMaire, S.A.; Hou, X.; Zhang, C.; Coselli, J.S.; Chen, L.; Wang, X.L.; Zhang, Y. and Shen, Y.H. (2009) Activation of the AMPK-FOXO3 pathway reduces fatty acid-induced increase in intracellular reactive oxygen species by upregulating thioredoxin. Diabetes, 58, 2246-2257.
128. Hou, X.; Song, J.; Li, X.N.; Zhang, L.; Wang, X.; Chen, L. and Shen, Y.H. (2010) Metformin reduces intracellular reactive oxygen species levels by upregulating expression of the antioxidant thioredoxin via the AMPK-FOXO3 pathway. Biochem. Biophys. Res. Commun., 396, 199-205.
129. Tomizawa, A.; Hattori, Y.; Inoue, T.; Hattori, S. and Kasai, K. (2010) Fenofibrate suppresses microvascular inflammation and apoptosis through adenosine monophosphate-activated protein kinase activation. Metabolism, [Epub ahead of print].
130. Fay, J.R.; Steele, V. and Crowell, J.A. (2009) Energy homeostasis and cancer prevention: the AMP-activated protein kinase. Cancer Prev. Res., (Phila Pa), 2, 301-309.
131. Libby, G.; Donnelly, L.A.; Donnan, P.T.; Alessi, D.R.; Morris, A.D. and Evans, J.M. (2009) New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care, 32, 1620-1625.
132. Hoppe, S.; Bierhoff, H.; Cado, I.; Weber, A.; Tiebe, M.; Grummt, I. and Voit, R. (2009) AMP-activated protein kinase adapts rRNA synthesis to cellular energy supply. Proc. Natl. Acad. Sci. USA, 106, 17781-17786.
133. Steinberg, G.R.; Michell, B.J.; van Denderen, B.J.; Watt, M.J.; Carey, A.L.; Fam, B.C.; Andrikopoulos, S.; Proietto, J.; Gorgun, C.Z.; Carling, D.; Hotamisligil, G.S.; Febbraio, M.A.; Kay, T.W. and Kemp, B.E. (2006) Tumor necrosis factor alpha-induced skeletal muscle insulin resistance involves suppression of AMP kinase signaling. Cell Metab., 4, 465-474.
134. Kewalramani, G.; Puthanveetil, P.; Wang, F.; Kim, M.S.; Deppe, S.; Abrahani, A.; Luciani, D.S.; Johnson, J.D. and Rodrigues, B. (2009) AMP-activated protein kinase confers protection against TNF-{alpha}-induced cardiac cell death. Cardiovasc. Res., 84, 42-53.
135. Bergheim, I.; Guo, L.; Davis, M.A.; Lambert, J.C.; Beier, J.I.; Duveau, I.; Luyendyk, J.P.; Roth, R.A. and Arteel, G.E. (2006) Metformin prevents alcohol-induced liver injury in the mouse: Critical role of plasminogen activator inhibitor-1. Gastroenterology, 130, 2099-2112.
136. Chanda, D.; Lee, C.H.; Kim, Y.H.; Noh, J.R.; Kim, D.K.; Park, J.H.; Hwang, J.H.; Lee, M.R.; Jeong, K.H.; Lee, I.K.; Kweon, G.R.; Shong, M.; Oh, G.T.; Chiang, J.Y. and Choi, H.S. (2009) Fenofibrate differentially regulates plasminogen activator inhibitor- 1 gene expression via adenosine monophosphate-activated protein kinase-dependent induction of orphan nuclear receptor small heterodimer partner. Hepatology, 50, 880-892.
137. Foller, M.; Sopjani, M.; Koka, S.; Gu, S.; Mahmud, H.; Wang, K.; Floride, E.; Schleicher, E.; Schulz, E.; Munzel, T. and Lang, F. (2009) Regulation of erythrocyte survival by AMP-activated protein kinase. FASEB J., 23, 1072-1080.
138. Bright, N.J.; Thornton, C. and Carling, D. (2009) The regulation and function of mammalian AMPK-related kinases. Acta Physiol. (Oxf)., 196, 15-26.
139. Stenstrom, K.; Takemori, H.; Bianchi, G.; Katz, A.I. and Bertorello, A.M. (2009) Blocking the salt-inducible kinase 1 network prevents the increases in cell sodium transport caused by a hypertension-linked mutation in human alpha-adducin. J. Hypertens., 27, 2452-2457.
140. Ramnanan, C.J.; McMullen, D.C.; Groom, A.G. and Storey, K.B. (2010) The regulation of AMPK signaling in a natural state of profound metabolic rate depression. Mol. Cell Biochem., 335, 91-105.
141. McGee, S.L.; Fairlie, E.; Garnham, A.P. and Hargreaves, M. (2009) Exercise-induced histone modifications in human skeletal muscle. J. Physiol., 587, 5951-5958.
142. Onken, B. and Driscoll, M. (2010) Metformin induces a dietary restriction-like state and the oxidative stress response to extend C. elegans Healthspan via AMPK, LKB1, and SKN-1. PLoS One, 5, e8758.
143. Martínez-Agustin, O.; Hernández-Morante, J.J.; Martínez-Plata, E.; Sánchez de Medina, F. and Garaulet, M. (2010) Differences in AMPK expression between subcutaneous and visceral adipose tissue in morbid obesity. Regul. Pept., 163, 31-36.
144. Higgs, G. (2004) Molecular genetics: the Emperor's clothes of drug discovery? Drug Discov. Today, 9, 727-729.
145. Steinberg, G.R. and Kemp, B.E. (2009) AMPK in Health and Disease. Physiol. Rev., 89, 1025-1078.
146. Benziane, B.; Bjornholm, M.; Lantier, L.; Viollet, B.; Zierath, J.R. and Chibalin, A.V. (2009) AMP-activated protein kinase activator A-769662 is an inhibitor of the Na(+)-K(+)-ATPase. Am. J. Physiol. Cell Physiol., 297, C1554-1566.
147. Han, C.Y. (2011) Ajoene, A Stable Garlic By-Product, Inhibits High Fat Diet-Induced Hepatic Steatosis and Oxidative Injury Through LKB1-Dependent AMPK Activation. Antioxid. Redox Signal., 14, 187-202.
148. Ahn, J.; Lee, H.; Kim, S.; Park, J. and Ha, T. (2011) Corrigendum to The anti-obesity effect of quercetin is mediated by the AMPK and MAPK signaling pathways. Biochem. Biophys. Res. Commun., 404, 579-579.
149. Kim, T.; Davis, J.; Zhang, A.J.; He, X. and Mathews, S.T. (2009) Curcumin activates AMPK and suppresses gluconeogenic gene expression in hepatoma cells. Biochem. Biophys. Res. Commun., 388, 377-382.
150. Egawa, T.; Hamada, T.; Ma, X.; Karaike, K.; Kameda, N.; Masuda, S.; Iwanaka, N. and Hayashi, T. (2011) Caffeine activates preferentially α1-isoform of 5'AMP-activated protein kinase in rat skeletal muscle. Acta. Physiologica., 201, 227-238.
151. Hoehn, K.L.; Salmon, A.B.; Hohnen-Behrens, C.; Turner, N.; Hoy, A.J.; Maghzal, G.J.; Stocker, R.; Van Remmen, H.; Kraegen, E.W.; Cooney, G.J.; Richardson, A.R. and James, D.E. (2009) Insulin resistance is a cellular antioxidant defense mechanism. Proc. Natl. Acad. Sci. USA, 106, 17787-17792.
152. Poudyal, H.; Campbell, F. and Brown, L. (2010) Olive leaf extract attenuates cardiac, hepatic, and metabolic changes in high carbohydrate-, high fat-fed rats. J. Nutr., 140, 946-953.
153. Poudyal, H.; Panchal, S. and Brown, L. (2010) Comparison of purple carrot juice and beta-carotene in a high-carbohydrate, highfat diet-fed rat model of the metabolic syndrome. Br. J. Nutr., 104, 1322-1332.
154. Veerapur, V.P.; Prabhakar, K.R.; Kandadi, M.R.; Srinivasan, K.K. and Unnikrishnan, M.K. (2010) Antidiabetic effect of Dodonaea viscosa aerial parts in high fat diet and low dose streptozotocininduced type 2 diabetic rats: A mechanistic approach. Pharm. Biol., 48, 1137-1148.
155. Hardie, D.G. and Carling, D. (1997) The AMP-activated protein kinase--fuel gauge of the mammalian cell? Eur. J. Biochem., 246, 259-273.
156. Winder, W.W. and Hardie, D.G. (1999) AMP-activated protein kinase, a metabolic master switch: possible roles in type 2 diabetes. Am. J. Physiol., 277, E1-10.
157. Wojtaszewski, J.F.; Nielsen, P.; Hansen, B.F.; Richter, E.A. and Kiens, B. (2000) Isoform-specific and exercise intensity-dependent activation of 5'-AMP-activated protein kinase in human skeletal muscle. J. Physiol., 528 Pt 1, 221-226.
158. Minokoshi, Y.; Kim, Y.B.; Peroni, O.D.; Fryer, L.G.; Muller, C.; Carling, D. and Kahn, B.B. (2002) Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature, 415, 339-343.
159. Woods, A.; Johnstone, S.R.; Dickerson, K.; Leiper, F.C.; Fryer, L.G.; Neumann, D.; Schlattner, U.; Wallimann, T.; Carlson, M. and Carling, D. (2003) LKB1 is the upstream kinase in the AMPactivated protein kinase cascade. Curr. Biol., 13, 2004-2008.
160. Carling, D. (2004) The AMP-activated protein kinase cascade-- a unifying system for energy control. Trends Biochem. Sci., 29, 18-24.
161. Hawley, S.A.; Pan, D.A.; Mustard, K.J.; Ross, L.; Bain, J.; Edelman, A.M.; Frenguelli, B.G. and Hardie, D.G. (2005) Calmodulindependent protein kinase kinase-beta is an alternative upstream kinase for AMP-activated protein kinase. Cell Metab., 2, 9-19.
162. Baur, J.A.; Pearson, K.J.; Price, N.L.; Jamieson, H.A.; Lerin, C.; Kalra, A.; Prabhu, V.V.; Allard, J.S.; Lopez-Lluch, G.; Lewis, K.; Pistell, P.J.; Poosala, S.; Becker, K.G.; Boss, O.; Gwinn, D.; Wang, M.; Ramaswamy, S.; Fishbein, K.W.; Spencer, R.G.; Lakatta, E.G.; Le Couteur, D.; Shaw, R.J.; Navas, P.; Puigserver, P.; Ingram, D.K.; de Cabo, R. and Sinclair, D.A. (2006) Resveratrol improves health and survival of mice on a high-calorie diet. Nature, 444, 337-342.
163. Narbonne, P. and Roy, R. (2009) Caenorhabditis elegans dauers need LKB1/AMPK to ration lipid reserves and ensure long-term survival. Nature, 457, 210-214.